{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"53.5","value":"8.85"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"title":"Conjugated Antibody Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.7","value":"15.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"90"}],"units":"Participants"}],"title":"Conjugated Antibody Cycle 2"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"title":"Conjugated Antibody Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"54.6","value":"8.66"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"title":"Total Antibody Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"56.5","value":"20.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"}],"units":"Participants"}],"title":"Total Antibody Cycle 2"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"title":"Total Antibody Cycle 3"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"title":"SG3199 Cycle 1"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"title":"SG3199 Cycle 2"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"title":"SG3199 Cycle 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"90"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received loncastuximab tesirine as an IV infusion over 30 minutes on Day 1 of each cycle (every 3 weeks) at a dose of 150 μg/kg Q3W for 2 cycles, then 75 μg/kg Q3W for subsequent cycles for up to one year or until disease progression, unacceptable toxicity, or other discontinuation criteria, whichever occurred first.","id":"OG000","title":"Loncastuximab Tesirine"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK population: All participants in the per-protocol population (all participants in the all-treated population without major protocol deviations) with at least 1 pre-Cycle 1 Day 1 and 1 post-dose valid assessment. Only participants with data available for analysis are presented.","reportingStatus":"POSTED","timeFrame":"Cycles 1 and 2: Day 1 pre-dose, and at 0, 4, 168 and 336 hours post-dose; Cycle 3: Day 1 pre-dose","title":"Apparent Terminal Half-life (Thalf) of Loncastuximab Tesirine Conjugated Antibody, Total Antibody and Warhead SG3199","type":"SECONDARY","unitOfMeasure":"days"}